Search Results



Your search for all items matches 234 pages

Showing 1 - 50


pancreatic cancer

David A. Tuveson, MD, PhD, on Progress in Pancreatic Cancer: Expert Perspective

David A. Tuveson, MD, PhD, of Cold Spring Harbor Laboratory, discusses the most lethal of cancers. Although treatments are improving, the challenges are great, including early detection of this malignancy, which metastasizes early in its development.

pancreatic cancer

Adding Adjuvant Erlotinib to Gemcitabine After R0 Resection of Pancreatic Cancer

The German phase III CONKO-005 trial has shown no significant benefit of adding adjuvant erlotinib (Tarceva) to gemcitabine after R0 resection in patients with pancreatic ductal adenocarcinoma. The findings were reported in the Journal of Clinical Oncology by Sinn et al. Study Details In the...

pancreatic cancer

Germline Mutations in Apparent Sporadic Pancreatic Adenocarcinoma

As reported by Shindo et al in the Journal of Clinical Oncology, deleterious germline mutations in known pancreatic cancer susceptibility genes were frequently found in patients with pancreatic cancer who do not have a reported family history of cancer. Study Details The study involved sequencing ...

hematologic malignancies
symptom management
supportive care
head and neck cancer
pancreatic cancer
solid tumors

NCCN Panelists Relay ‘What’s Hot’ in Their Fields

AT THE NATIONAL Comprehensive Cancer Network® (NCCN®) 22nd Annual Conference, experts from several fields met with journalists to highlight “what’s hot” in their specialties. The ASCO Post captured that conversation.  Myeloproliferative Neoplasms Guidelines  NCCN HAS LAUNCHED new NCCN Clinical...

pancreatic cancer

Stereotactic Body Radiotherapy for Poor Performance Status Patients With Pancreatic Cancer

There are few data to guide the management of nonmetastatic pancreatic ductal adenocarcinoma in patients who are elderly or have a poor performance status. Although most such patients are offered supportive care or gemcitabine alone, the addition of stereotactic body radiotherapy may improve...

pancreatic cancer

Has a New Standard Really Been Established for the Adjuvant Treatment of Pancreatic Cancer?

THE PAST YEAR has undoubtedly been a disappointing one as far as clinical advances in pancreatic cancer go. No fewer than five high-profile randomized phase II or III trials in this setting reported negative results in 2016, ranging from next-generation cytotoxic agents1 to novel immunotherapeutic ...

pancreatic cancer

Addition of Adjuvant Capecitabine to Gemcitabine Improves Survival in Patients With Resected Pancreatic Cancer

IN THE EUROPEAN phase III ESPAC-4 trial reported in The Lancet, John P. Neoptolemos, MD, of the Liverpool Clinical and Cancer Research UK Trials Unit, University of Liverpool, and colleagues found that adding adjuvant capecitabine to gemcitabine significantly improved overall survival in patients...

pancreatic cancer

WCHN Launches Trial to Screen Newly Diagnosed Patients With Diabetes for Early-Stage Pancreatic Cancer

Western Connecticut Health Network (WCHN) has announced the launch of a 3-year research study that will investigate the link between new-onset diabetes and pancreatic cancer. The main goal of the study is to detect the often lethal cancer at a curable stage. The study was developed by a team of...

pancreatic cancer

ESMO World GI 2017: Pegilodecakin Plus FOLFOX in Advanced Pancreatic Cancer

Clinical data on an investigational immuno-oncology drug pegilodecakin (PEGylated human interleukin-10, also known as AM0010) was presented by Hecht et al at the ESMO 19th World Congress on Gastrointestinal Cancer in Barcelona, Spain (Abstract O-004). Pegilodecakin is being evaluated in an ongoing...

pancreatic cancer

WCHN Launches Trial to Screen Newly Diagnosed Patients With Diabetes for Early-Stage Pancreatic Cancer

Western Connecticut Health Network (WCHN) has announced the launch of a 3-year research study that will investigate the link between new-onset diabetes and pancreatic cancer. The main goal is to detect the often lethal cancer at a curable stage. The study was developed by a team of physicians and...

pancreatic cancer

Adding Vandetanib to Gemcitabine in Locally Advanced or Metastatic Pancreatic Carcinoma

In a UK phase II trial reported in The Lancet Oncology, Middleton et al found that adding the multi–tyrosine kinase inhibitor vandetanib (Caprelsa) to gemcitabine did not improve overall survival in patients with previously untreated locally advanced or metastatic pancreatic carcinoma. John P....

solid tumors
pancreatic cancer

SNMMI 2017: Immuno-PET Shows Promise for Detecting and Treating Pancreatic Tumors, Other Solid Tumors

A first-in-human study presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Abstract 385) demonstrated the feasibility and safety of imaging with the novel human monoclonal antibody HuMab-5B1, to enable highly specific targeting for the cancer...

pancreatic cancer

ASCO 2017: Adding PEGPH20 to Standard Treatment in Metastatic Pancreatic Cancer May Delay Disease Progression

By adding an experimental drug to a standard chemotherapy regimen, a subset of patients with metastatic pancreatic cancer had a significantly longer period before the cancer progressed as compared with those who received the standard treatment, according to a phase II clinical trial led by an...

pancreatic cancer

ESTRO 2017: Study Suggests Role for Radiotherapy in Extending Survival in Patients With Early-Stage Pancreatic Cancer

Radiotherapy at a high enough dose may increase survival in early-stage pancreatic cancer, according to research presented at the European Society for Radiotherapy & Oncology (ESTRO) 36 Conference.1 Previous research has suggested that radiotherapy may be of little help in this setting. The...

pancreatic cancer

Hydroxychloroquine Boosts Antitumor Activity of Neoadjuvant Chemotherapy for Pancreatic Cancer

Adding hydroxychloroquine, an inhibitor of autophagy, to neoadjuvant chemotherapy for pancreatic cancer increases its efficacy and alters the tumor’s molecular profile in a way that may render the tumor more susceptible to immune checkpoint inhibitors, according to interim data from a phase II...

pancreatic cancer

ESTRO 2017: Study Suggests Role for Radiotherapy in Extending Survival in Patients With Early-Stage Pancreatic Cancer

Radiotherapy at a high enough dose may increase survival in early-stage pancreatic cancer, according to research presented at the European Society for Radiotherapy & Oncology (ESTRO) 36 Conference (Abstract OC-0426). Previous research has suggested that radiotherapy may be of little help to...

pancreatic cancer

Update to ASCO Clinical Practice Guideline on Potentially Curable Pancreatic Cancer

An ASCO clinical practice guideline update, reported by Khorana et al in the Journal of Clinical Oncology, includes the recommendation of gemcitabine-capecitabine doublet therapy as an adjuvant therapy option in potentially curable pancreatic cancer. The updated recommendation (4.1) modifies the...

pancreatic cancer

Onset of Diabetes or Its Rapid Deterioration Can Be an Early Warning Sign of Pancreatic Cancer

The onset of diabetes, or a rapid deterioration in existing diabetes that requires more aggressive treatment, could be a sign of early, hidden pancreatic cancer, according to research presented by Autier et al at the 2017 European Cancer Congress ­(Abstract 540).1 Study Design and Key Findings...

pancreatic cancer

Cigarette Smoking and Survival in Pancreatic Cancer

A study of data from large prospective U.S. cohorts has shown that current cigarette smoking, greater pack-years, and heavy smoking were associated with poorer survival among patients with pancreatic cancer. The study was reported by Yuan et al in the Journal of Clinical Oncology. Study Details...

pancreatic cancer

AACR 2017: PRMT1 Identified as Potential Druggable Target for Pancreatic Cancer

A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma, according to results presented by Giuliani et al the 2017 Annual Meeting of the American Association for Cancer Research (AACR) in Washington, DC (Abstract 3016)....

pancreatic cancer

Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment

Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the evidence for using neoadjuvant and adjuvant systemic therapies in resectable and borderline resectable pancreatic cancer.

pancreatic cancer

SSO 2017: Preclinical Trial Shows Intratumoral Vaccination Induces Antitumor Response in Pancreatic Cancer

Building on their previous research focusing on intratumoral vaccination for the most common form of pancreatic cancer, investigators from Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School have shown that in a mouse model of early-stage resected pancreatic...

pancreatic cancer

Adding Vandetanib to Gemcitabine in Locally Advanced or Metastatic Pancreatic Carcinoma

In a UK phase II trial reported in The Lancet Oncology, Middleton et al found that adding the multi–tyrosine kinase inhibitor vandetanib (Caprelsa) to gemcitabine did not improve overall survival in patients with previously untreated locally advanced or metastatic pancreatic carcinoma. Study ...

pancreatic cancer

Expert Point of View: Allyson J. Ocean, MD

Allyson J. Ocean, MD, a pancreatic cancer specialist at New York-Presbyterian Hospital/Weill Cornell Medical Center and Associate Professor of Medicine at the Weill Medical College of Cornell University, commented on these study findings. “While I applaud the authors for the data presented, the...

pancreatic cancer

Update on Overall Survival for Newly Diagnosed Patients With Metastatic Pancreatic Cancer

Although “treatment advances” and “precision medicine” are today’s buzz words in oncology, they don’t apply equally to all malignancies. For instance, median overall survival for newly diagnosed patients with metastatic pancreatic cancer has not improved much over the past 20 years, according to...

pancreatic cancer

Two Migration Proteins Boost Predictive Value of Pancreatic Cancer Biomarker

Adding two blood-borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic cancer to detect early-stage disease, a research team from The University of Texas MD Anderson Cancer Center reported in a study by Balasenthil et al in the ...

pancreatic cancer

First-in-Class Rovalpituzumab Tesirine in Recurrent Small Cell Lung Cancer

In a phase I study reported in The Lancet Oncology, Charles M. Rudin, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that rovalpituzumab tesirine, a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), produced responses in patients with...

pancreatic cancer

Circulating Tumor DNA as a Prognostic Marker in Pancreatic Cancer

Translational research in pancreatic adenocarcinoma has been limited by the difficulty of obtaining sufficient quality and quantity tumor tissue from patients. A study by Pietrasz et al assessing the feasibility and prognostic value of circulating tumor DNA (ctDNA) in pancreatic adenocarcinoma has...

pancreatic cancer
gastrointestinal cancer
colorectal cancer

‘Collateral Lethality’ May Offer New Therapeutic Approach to Cancers of the Pancreas, Stomach, and Colon

Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as “collateral lethality,” which may create new options for the development of therapies for several cancers. Scientists at The University of Texas MD...

pancreatic cancer

Study Finds Addition of Adjuvant Capecitabine to Gemcitabine Improves Survival in Resected Pancreatic Cancer

In the European phase III ESPAC-4 trial reported in The Lancet, Neoptolemos et al found that adding adjuvant capecitabine to gemcitabine significantly improved overall survival in patients with resected pancreatic cancer. Study Details In the open-label trial, 730 patients from 92 hospitals in...

pancreatic cancer

Sarah E. Hoffe, MD, on Pancreatic Cancer and SBRT: Pros and Cons

Sarah E. Hoffe, MD, of the Moffitt Cancer Center, discusses the controversial role of radiation in the treatment of pancreatic cancer, recent advances in delivering short courses of high-dose stereotactic body radiation therapy, and how best to integrate this new modality in borderline and locally...

pancreatic cancer
hepatobiliary cancer

Eileen M. O’Reilly, MD, on Pancreatic and Hepatobiliary Cancers: Selecting High-Impact Targets

Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses a range of topics, including tyrosine kinase inhibitors, immune therapies, targeted approaches, and DNA damage repair strategies.

pancreatic cancer

Mark Talamonti, MD, on Pancreatic Cancer: Minimally Invasive Resection

Mark Talamonti, MD, of NorthShore University Health System, discusses the technical prerequisites for minimally invasive surgery in pancreatic cancers and the potential benefits to patients.

pancreatic cancer

Circulating Tumor DNA May Serve as a Prognostic Marker in Pancreatic Cancer

Translational research in pancreatic adenocarcinoma has been limited by the difficulty of obtaining sufficient quality and quantity tumor tissue from patients. A study by Pietrasz et al assessing the feasibility and prognostic value of circulating tumor DNA (ctDNA) in pancreatic adenocarcinoma has...

pancreatic cancer

Recent Progress and Concepts in Pancreatic Cancer

November is National Pancreatic Cancer Awareness Month, the impetus for this article. Pancreatic cancer is a huge health challenge. It's the eighth most common cancer in the United States and the fourth most common cause of cancer deaths but is expected to become the second most common cause of...

pancreatic cancer

Impact of Neoadjuvant Therapy on Survival in Resectable Pancreatic Cancer

In a propensity score–matched analysis of National Cancer Database data reported in the Journal of Clinical Oncology, Mokdad et al found that neoadjuvant therapy followed by resection was associated with a survival benefit vs upfront resection. Patricio M. Polanco, MD, of the Division of Surgical...

pancreatic cancer

Let’s Win: Innovative Online Community Offers Guidance to Patients With Pancreatic Cancer and Their Families

Let’s Win is an online community for persons with pancreatic cancer (www.letswinpc.org), but it is far more than a typical support group. Let’s Win propels interested users toward cutting-edge research, based on its founders’ commitment that no patient with pancreatic cancer should settle on the...

pancreatic cancer

Vaccines May Boost Immune Responsiveness of Pancreatic Tumors

Pancreatic cancer has been notably unresponsive to immunotherapeutic approaches, but a Stand Up 2 Cancer Dream Team believes their research can change that. Team co-leader Elizabeth Jaffee, MD, Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, ...

pancreatic cancer

Scientists Are Boosting Immune Responses in Pancreatic Tumors

The successes observed with various immune oncologic treatment approaches have largely bypassed pancreatic cancer, but this may be about to change, based on emerging insights into how and why these tumors evade attacks by T cells. At the 2nd International Cancer Immunotherapy Conference, two...

pancreatic cancer

Precision Promise Clinical Trial Focuses on Precision Medicine, Collaboration, and Data-Sharing in Pancreatic Cancer

The Pancreatic Cancer Action Network recently announced Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer. The organization also announced the 12 initial Precision Promise Clinical Trial Consortium sites selected to...

pancreatic cancer

Analysis Indicates Survival Advantage With Neoadjuvant Therapy in Resectable Pancreatic Cancer

In a propensity score–matched analysis of National Cancer Database data reported in the Journal of Clinical Oncology, Mokdad et al found that neoadjuvant therapy followed by resection was associated with a survival benefit vs upfront resection. Study Details The analysis included adults...

pancreatic cancer

Comparison of Second-Line Treatments in Advanced Pancreatic Cancer After Gemcitabine-Based Chemotherapy

In the Canadian phase III PANCREOX trial reported in the Journal of Clinical Oncology, Gill et al found no benefit of modified FOLFOX6 (infusional fluorouracil [5-FU], leucovorin, and oxaliplatin) vs infusional 5-FU/leucovorin as second-line treatment in patients with advanced pancreatic cancer who ...

pancreatic cancer

Overall Survival With Everolimus in Advanced Pancreatic Neuroendocrine Tumors in the RADIANT-3 Trial

As reported by Yao et al in the Journal of Clinical Oncology, the final overall survival analysis from the phase III RADIANT-3 trial showed a median survival of 44.0 months among patients with advanced pancreatic neuroendocrine tumors initially randomized to receive everolimus (Afinitor, Zortress)...

pancreatic cancer

AACR, Pancreatic Cancer Action Network Awards Research Grants to Early-Career Investigators

The American Association for Cancer Research (AACR) and the Pancreatic Cancer Action Network awarded nine grants to outstanding scientists who will undertake novel research in the field of pancreatic cancer. “By recruiting the brightest scientists with the most novel ideas, we continue to build a ...

pancreatic cancer

ASCO Guideline on Metastatic Pancreatic Cancer

As reported in the Journal of Clinical Oncology by Davendra P.S. Sohal, MD, MPH, of Cleveland Clinic, and colleagues, ASCO has released a clinical practice guideline on the treatment of patients with metastatic pancreatic cancer.1 Recommendations are based on an expert panel systematic review of...

pancreatic cancer

ASCO Guideline on Treatment of Locally Advanced, Unresectable Pancreatic Cancer

As reported by Edward P. Balaban, DO, FASCO, of Penn State Hershey Cancer Institute, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on the treatment of locally advanced, unresectable pancreatic cancer.1 The recommendations are based on expert...

pancreatic cancer

ASCO 2016 Guidelines for the Treatment of Pancreatic Cancer: Why Another Guideline?

The 5-year survival rate of those diagnosed with pancreatic cancer remains stubbornly fixed around 5%. Even in the 20% of cases in which surgical resection is undertaken for curative intent, the 5-year survival rate after surgery is 20% to 30%. As we make progress in other cancers with decreasing...

pancreatic cancer

ASCO Guideline on Potentially Curable Pancreatic Cancer

As reported in the Journal of Clinical Oncology by Alok A. Khorana, MD, of Cleveland Clinic, and colleagues, ASCO has released a clinical practice guideline on the treatment of potentially curable pancreatic cancer.1 The recommendations are based on an expert panel systematic review of the...

pancreatic cancer

Precision Medicine Clinical Trial for Metastatic Pancreatic Cancer Now Open at Multiple Sites

The first clinical trial to compare standard-of-care chemotherapy with molecularly tailored therapy (also known as precision medicine) for metastatic pancreatic cancer is now enrolling patients at multiple sites around the country. Patients who have been treated with one round of chemotherapy for...

gastrointestinal cancer
pancreatic cancer
colorectal cancer

Treatment Update in Gastric, Pancreatic, and Colorectal Cancers

Although new gastrointestinal cancers are on the rise, advancements in their treatment, as well as the upcoming results of perioperative trials, could prove to be “clinical practice game-changers,” declared Thomas J. George, Jr, MD, FACP, at the 2016 Community Oncology Conference in Orlando,...

Advertisement



Advertisement


Advertisement